Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
Boga, S.B., Alhassan, A.B., Cooper, A.B., Doll, R., Shih, N.Y., Shipps, G., Deng, Y., Zhu, H., Nan, Y., Sun, R., Zhu, L., Desai, J., Patel, M., Muppalla, K., Gao, X., Wang, J., Yao, X., Kelly, J., Gudipati, S., Paliwal, S., Tsui, H.C., Wang, T., Sherborne, B., Xiao, L., Hruza, A., Buevich, A., Zhang, L.K., Hesk, D., Samatar, A.A., Carr, D., Long, B., Black, S., Dayananth, P., Windsor, W., Kirschmeier, P., Bishop, R.(2018) Bioorg Med Chem Lett 28: 2029-2034
- PubMed: 29748051 
- DOI: https://doi.org/10.1016/j.bmcl.2018.04.063
- Primary Citation of Related Structures:  
6CPW - PubMed Abstract: 
Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 μM h; F% = 0) which precluded further development ...